Fig. 3
From: Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
Decrease in median monthly migraine days (MMDs), analgesic use days (ADs), and triptan use days (TDs) among the 76 patients who completed treatment (panel a); six-month decrease in median scale scores in patients with available data (Panel b). All comparisons with a double asterisk have a P value < 0.001, while the comparison with a single asterisk has a P value = 0.001. ASC indicates Allodynia Symptom Checklist; BDI, Beck Depression Inventory; GAD-7, Generalized Anxiety Disorder Questionnaire; HIT-6, Headache Impact Test; MIDAS, Migraine Impact and Disability Assessment Score; NRS, Numerical Rating Scale